Background Chimeric antigen receptor (CAR) T-cell therapy is a promising option for
patients with heavily treated multiple myeloma. Point-of-care manufacturing can increase the …

Chimeric antigen receptor T-cells targeting the CD19 antigen have achieved impressive
results in patients with relapsed/refractory (R/R) B-cell malignancies, leading to their …

Relapse after CD19-directed chimeric antigen receptor (CAR)-T cell therapy remains a
major challenge in B-cell acute lymphoblastic leukaemia (ALL) and B-cell non-Hodgkin …

CD19-directed immunotherapies have revolutionized the treatment of advanced B-cell acute
lymphoblastic leukemia (B-ALL). Despite initial impressive rates of complete remission (CR) …

CD28‐based CD19 chimaeric antigen receptor‐modified (CAR‐) Tcells were recently FDA‐
approved for adult acute lymphoblastic leukaemia (ALL). We report long‐term outcome of 37 …

We evaluated outcomes of 18 patients with isolated extramedullary disease (iEMD)
relapsed/refractory (R/R) B‐cell acute lymphoblastic leukemia (B‐ALL) treated with the …

Varnimcabtagene autoleucel (var‐cel) is an academic anti‐CD19 chimeric antigen receptor
(CAR) product used for the treatment of non‐Hodgkin lymphoma (NHL) in the CART19‐BE …

Background This study aimed to describe documented infections associated with
postinfusion fever after CAR T-cell therapy and to evaluate daily changes in vital signs …

Chimeric Antigen Receptor T-cell therapy (CAR-T) targeting CD19 has transformed the
management of relapsed/refractory (r/r) B-Acute Lymphoblastic Leukemia (B-ALL), with FDA …

The introduction of immunotherapy with monoclonal antibodies (mAbs) is a major step
forward for adults and children with B-lineage acute lymphoblastic leukaemia (ALL) and will …